Tafamidis is entering the clinical arena for the treatment of transthyretin-related cardiomyopathy: certainties and unmet needs. Rapezzi C, Aimo A, Emdin M. Eur J Heart Fail 2021;23:286-289.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Rapezzi C, Aimo A, Emdin M. Tafamidis is entering the clinical arena for the treatment of transthyretin-related cardiomyopathy: certainties and unmet needs. Eur J Heart Fail 2021;23:286-289.
PMID: 33443315